Determinants of patient screen failures in Phase 1 clinical trials

Alexandra McKane, Chao Sima, Ramesk K Ramanathan, Gayle Jameson, Cathy Mast, Erica White, Sharon Fleck, Molly Downhour, Daniel D. Von Hoff, Glen J. Weiss

Research output: Contribution to journalArticle

Abstract

Objective Certain eligibility criteria for Phase 1 cancer clinical trials may impede successful patient enrollment onto a study. We evaluated patient-specific or study-specific reasons for screen failures on Phase 1 oncology clinical trials and discuss factors which may inhibit subject enrollment. Methods Thirty-eight Phase 1 clinical trials for solid tumors meeting eligibility criteria and opened for enrollment between February 2006 and February 2011 at one oncology Phase 1 program were examined. Categorical reasons for screen failures and patients' demographics were examined and compared to characteristics of patients that successfully enrolled on a Phase 1 trial. Results There were a total of 583 successful Phase 1 enrollment and dose administration events out of 773 Phase 1 consent events (75.4 % dose success rate). The three most common reasons for screen failure were: out of protocol-specified range for chemistry, development of an interval medical issue that precluded proceeding with study participation, and subject declining participation after signing consent. Living further away from the Phase 1 program and receipt of fewer prior lines of systemic chemotherapy were significantly associated with increased screen failures. Conclusion Screen failures for Phase 1 studies are not uncommon (24.6 %). When a protocol required tumor or host analyte is not required, most screen failures are due to out of protocol-specified range for chemistry or the development of an interval medical issue. Screen failure rates were increased when patients had longer travel distances and fewer prior lines of systemic chemotherapy.

Original languageEnglish (US)
Pages (from-to)774-779
Number of pages6
JournalInvestigational New Drugs
Volume31
Issue number3
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Clinical Trials, Phase I
Drug Therapy
Neoplasms
Demography

Keywords

  • Clinical trials
  • Eligibility criteria
  • Phase 1
  • Screen failure
  • Study design

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

McKane, A., Sima, C., Ramanathan, R. K., Jameson, G., Mast, C., White, E., ... Weiss, G. J. (2013). Determinants of patient screen failures in Phase 1 clinical trials. Investigational New Drugs, 31(3), 774-779. https://doi.org/10.1007/s10637-012-9894-7

Determinants of patient screen failures in Phase 1 clinical trials. / McKane, Alexandra; Sima, Chao; Ramanathan, Ramesk K; Jameson, Gayle; Mast, Cathy; White, Erica; Fleck, Sharon; Downhour, Molly; Von Hoff, Daniel D.; Weiss, Glen J.

In: Investigational New Drugs, Vol. 31, No. 3, 06.2013, p. 774-779.

Research output: Contribution to journalArticle

McKane, A, Sima, C, Ramanathan, RK, Jameson, G, Mast, C, White, E, Fleck, S, Downhour, M, Von Hoff, DD & Weiss, GJ 2013, 'Determinants of patient screen failures in Phase 1 clinical trials', Investigational New Drugs, vol. 31, no. 3, pp. 774-779. https://doi.org/10.1007/s10637-012-9894-7
McKane, Alexandra ; Sima, Chao ; Ramanathan, Ramesk K ; Jameson, Gayle ; Mast, Cathy ; White, Erica ; Fleck, Sharon ; Downhour, Molly ; Von Hoff, Daniel D. ; Weiss, Glen J. / Determinants of patient screen failures in Phase 1 clinical trials. In: Investigational New Drugs. 2013 ; Vol. 31, No. 3. pp. 774-779.
@article{e4442c6aee794bf0af646da8995d2798,
title = "Determinants of patient screen failures in Phase 1 clinical trials",
abstract = "Objective Certain eligibility criteria for Phase 1 cancer clinical trials may impede successful patient enrollment onto a study. We evaluated patient-specific or study-specific reasons for screen failures on Phase 1 oncology clinical trials and discuss factors which may inhibit subject enrollment. Methods Thirty-eight Phase 1 clinical trials for solid tumors meeting eligibility criteria and opened for enrollment between February 2006 and February 2011 at one oncology Phase 1 program were examined. Categorical reasons for screen failures and patients' demographics were examined and compared to characteristics of patients that successfully enrolled on a Phase 1 trial. Results There were a total of 583 successful Phase 1 enrollment and dose administration events out of 773 Phase 1 consent events (75.4 {\%} dose success rate). The three most common reasons for screen failure were: out of protocol-specified range for chemistry, development of an interval medical issue that precluded proceeding with study participation, and subject declining participation after signing consent. Living further away from the Phase 1 program and receipt of fewer prior lines of systemic chemotherapy were significantly associated with increased screen failures. Conclusion Screen failures for Phase 1 studies are not uncommon (24.6 {\%}). When a protocol required tumor or host analyte is not required, most screen failures are due to out of protocol-specified range for chemistry or the development of an interval medical issue. Screen failure rates were increased when patients had longer travel distances and fewer prior lines of systemic chemotherapy.",
keywords = "Clinical trials, Eligibility criteria, Phase 1, Screen failure, Study design",
author = "Alexandra McKane and Chao Sima and Ramanathan, {Ramesk K} and Gayle Jameson and Cathy Mast and Erica White and Sharon Fleck and Molly Downhour and {Von Hoff}, {Daniel D.} and Weiss, {Glen J.}",
year = "2013",
month = "6",
doi = "10.1007/s10637-012-9894-7",
language = "English (US)",
volume = "31",
pages = "774--779",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Determinants of patient screen failures in Phase 1 clinical trials

AU - McKane, Alexandra

AU - Sima, Chao

AU - Ramanathan, Ramesk K

AU - Jameson, Gayle

AU - Mast, Cathy

AU - White, Erica

AU - Fleck, Sharon

AU - Downhour, Molly

AU - Von Hoff, Daniel D.

AU - Weiss, Glen J.

PY - 2013/6

Y1 - 2013/6

N2 - Objective Certain eligibility criteria for Phase 1 cancer clinical trials may impede successful patient enrollment onto a study. We evaluated patient-specific or study-specific reasons for screen failures on Phase 1 oncology clinical trials and discuss factors which may inhibit subject enrollment. Methods Thirty-eight Phase 1 clinical trials for solid tumors meeting eligibility criteria and opened for enrollment between February 2006 and February 2011 at one oncology Phase 1 program were examined. Categorical reasons for screen failures and patients' demographics were examined and compared to characteristics of patients that successfully enrolled on a Phase 1 trial. Results There were a total of 583 successful Phase 1 enrollment and dose administration events out of 773 Phase 1 consent events (75.4 % dose success rate). The three most common reasons for screen failure were: out of protocol-specified range for chemistry, development of an interval medical issue that precluded proceeding with study participation, and subject declining participation after signing consent. Living further away from the Phase 1 program and receipt of fewer prior lines of systemic chemotherapy were significantly associated with increased screen failures. Conclusion Screen failures for Phase 1 studies are not uncommon (24.6 %). When a protocol required tumor or host analyte is not required, most screen failures are due to out of protocol-specified range for chemistry or the development of an interval medical issue. Screen failure rates were increased when patients had longer travel distances and fewer prior lines of systemic chemotherapy.

AB - Objective Certain eligibility criteria for Phase 1 cancer clinical trials may impede successful patient enrollment onto a study. We evaluated patient-specific or study-specific reasons for screen failures on Phase 1 oncology clinical trials and discuss factors which may inhibit subject enrollment. Methods Thirty-eight Phase 1 clinical trials for solid tumors meeting eligibility criteria and opened for enrollment between February 2006 and February 2011 at one oncology Phase 1 program were examined. Categorical reasons for screen failures and patients' demographics were examined and compared to characteristics of patients that successfully enrolled on a Phase 1 trial. Results There were a total of 583 successful Phase 1 enrollment and dose administration events out of 773 Phase 1 consent events (75.4 % dose success rate). The three most common reasons for screen failure were: out of protocol-specified range for chemistry, development of an interval medical issue that precluded proceeding with study participation, and subject declining participation after signing consent. Living further away from the Phase 1 program and receipt of fewer prior lines of systemic chemotherapy were significantly associated with increased screen failures. Conclusion Screen failures for Phase 1 studies are not uncommon (24.6 %). When a protocol required tumor or host analyte is not required, most screen failures are due to out of protocol-specified range for chemistry or the development of an interval medical issue. Screen failure rates were increased when patients had longer travel distances and fewer prior lines of systemic chemotherapy.

KW - Clinical trials

KW - Eligibility criteria

KW - Phase 1

KW - Screen failure

KW - Study design

UR - http://www.scopus.com/inward/record.url?scp=84879088944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879088944&partnerID=8YFLogxK

U2 - 10.1007/s10637-012-9894-7

DO - 10.1007/s10637-012-9894-7

M3 - Article

C2 - 23135779

AN - SCOPUS:84879088944

VL - 31

SP - 774

EP - 779

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -